Silence Therapeutics plc ADR | Micro-cap | Healthcare
$4.81
-5.69%
| Silence Therapeutics Stock Comparison:
Silence Therapeutics vs VertexSilence Therapeutics vs RegeneronSilence Therapeutics vs VerastemSilence Therapeutics vs CodexisSilence Therapeutics vs HumacyteSilence Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 224.0K
Gross Profit 139.0K 62.05%
Operating Income -22.6M -10,106.70%
Net Income -27.4M -12,211.61%
EPS (Diluted) $-0.57

Balance Sheet Metrics

Total Assets 165.2M
Total Liabilities 71.1M
Shareholders Equity 94.2M
Debt to Equity 0.75

Cash Flow Metrics

Operating Cash Flow -25.2M
Free Cash Flow -21.8M

Revenue & Profitability Trend

Silence Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i43.3M25.4M17.5M12.4M5.5M
Cost of Goods Sold i11.8M10.3M10.9M7.5M3.8M
Gross Profit i31.4M15.1M6.6M5.0M1.7M
Gross Margin % i72.7%59.3%37.8%39.9%31.3%
Operating Expenses
Research & Development i67.9M44.0M35.6M30.8M20.2M
Selling, General & Administrative i26.9M20.6M19.6M20.0M14.0M
Other Operating Expenses i-13.7M---3.4M
Total Operating Expenses i81.0M64.7M55.2M50.8M37.6M
Operating Income i-63.3M-49.6M-48.6M-45.8M-35.8M
Operating Margin % i-146.4%-195.5%-277.7%-369.0%-654.3%
Non-Operating Items
Interest Income i4.5M1.4M226.0K10.0K129.0K
Interest Expense i-34.0K47.0K8.0K16.0K
Other Non-Operating Income14.4M-2.1M1.0M-44.0K-307.0K
Pre-tax Income i-44.5M-50.3M-47.4M-45.9M-36.0M
Income Tax i845.0K-7.0M-6.9M-6.4M-3.5M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-45.3M-43.3M-40.5M-39.4M-32.5M
Net Margin % i-104.7%-170.5%-231.4%-317.4%-594.0%
Key Metrics
EBITDA i-63.4M-47.7M-47.9M-45.4M-35.2M
EPS (Basic) i$-0.99$-1.17$-1.26$-1.33$-1.19
EPS (Diluted) i$-0.99$-1.17$-1.26$-1.33$-1.19
Basic Shares Outstanding i4625074128803558259347112388482321958457
Diluted Shares Outstanding i4625074128803558259347112388482321958457

Income Statement Trend

Silence Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i121.3M54.0M54.8M73.5M27.4M
Short-term Investments i26.0M016.3M010.0M
Accounts Receivable i972.0K228.0K915.0K331.0K29.3M
Inventory i-----
Other Current Assets-----
Total Current Assets i187.4M81.0M96.7M86.3M76.4M
Non-Current Assets
Property, Plant & Equipment i157.0K503.0K498.0K345.0K4.5M
Goodwill i19.1M16.0M16.3M15.2M16.3M
Intangible Assets i312.0K284.0K320.0K24.0K17.0K
Long-term Investments-----
Other Non-Current Assets-----
Total Non-Current Assets i15.3M12.8M10.8M9.9M9.6M
Total Assets i202.6M93.8M107.5M96.2M86.0M
Liabilities
Current Liabilities
Accounts Payable i3.7M2.6M3.2M4.1M2.3M
Short-term Debt i117.0K179.0K446.0K137.0K341.0K
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i16.8M17.8M21.9M15.2M25.6M
Non-Current Liabilities
Long-term Debt i093.0K0--
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i51.8M59.0M63.5M72.5M51.3M
Total Liabilities i68.6M76.8M85.4M87.7M76.9M
Equity
Common Stock i10.3M5.9M5.4M4.5M4.2M
Retained Earnings i-474.0M-304.6M-263.3M-223.0M-184.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i134.0M17.0M22.1M8.5M9.1M
Key Metrics
Total Debt i117.0K272.0K446.0K137.0K341.0K
Working Capital i170.5M63.3M74.7M71.2M50.8M

Balance Sheet Composition

Silence Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-45.3M-50.3M-47.4M-45.9M-36.0M
Depreciation & Amortization i593.0K498.0K482.0K427.0K496.0K
Stock-Based Compensation i16.3M13.0M10.3M8.6M4.4M
Working Capital Changes i-33.5M-11.7M-9.7M36.4M17.4M
Operating Cash Flow i-65.6M-47.8M-47.6M4.1M-15.4M
Investing Activities
Capital Expenditures i-211.0K-45.0K-140.0K-1.3M-508.0K
Acquisitions i-----
Investment Purchases i-139.2M-20.7M-16.1M00
Investment Sales i117.4M36.2M010.0M10.0M
Investing Cash Flow i-22.0M15.5M-16.3M8.7M8.9M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i--174.0K-190.0K-211.0K-402.0K
Financing Cash Flow i142.1M25.2M43.0M30.7M15.4M
Free Cash Flow i-67.9M-39.4M-45.9M5.5M-11.3M
Net Change in Cash i54.6M-7.1M-20.8M43.5M8.9M

Cash Flow Trend

Silence Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -4.86
Forward P/E -6.41
Price to Book 2.41
Price to Sales 8.36
PEG Ratio -0.14

Profitability Ratios

Profit Margin -291.24%
Operating Margin -9,048.21%
Return on Equity -66.96%
Return on Assets -22.25%

Financial Health

Current Ratio 10.06
Debt to Equity 0.00
Beta 1.39

Per Share Data

EPS (TTM) $-1.68
Book Value per Share $1.99
Revenue per Share $0.58

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
sln204.0M-4.862.41-66.96%-291.24%0.00
Vertex 124.1B27.775.8322.77%31.86%8.89
Regeneron 61.2B14.642.0215.34%31.37%9.04
Verastem 246.6M-2.5315.78-437.92%0.00%234.95
Codexis 226.6M-2.824.43-111.00%-113.67%124.00
Humacyte 393.1M-1.2059.42282.33%0.00%2,072.16

Financial data is updated regularly. All figures are in the company's reporting currency.